세계의 임상시험 지원 소프트웨어 솔루션 시장 : 시장 규모, 점유율 및 동향 분석(제품별, 제공 방식별, 상별, 최종 용도별, 지역별), 부문별 예측(2025-2033년)

Clinical Trials Support Software Solutions Market Summary

The global clinical trials support software solutions market size was estimated at USD 11.12 billion in 2024 and is projected to reach USD 28.76 billion by 2033, growing at a CAGR of 10.9% from 2025 to 2033. Increasing research and development activities by biopharma and pharma companies are among the key trends escalating market growth.

In addition, the growing incorporation of software solutions in clinical trials is also projected to provide a fillip to the market growth. Furthermore, the increasing outsourcing and externalization of clinical trials by the majority of the prominent pharmaceutical and biotechnological companies is presumed to be responsible for driving the market at an unprecedented rate throughout the forecast period.

The stringent regulatory framework for clinical trials and a growing emphasis on safety monitoring significantly drive the adoption of clinical trial support software solutions in developed markets. For instance, agencies such as the U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) are tightening clinical trial registration requirements and actively promoting clinical data transparency and sharing. Global health authorities are increasingly implementing strategic policies to strengthen clinical trial governance and promote the use of digital technologies in research settings. For instance, in May 2025, the World Health Organization (WHO) introduced the global action plan to strengthen clinical trial ecosystems, which prioritizes the adoption of digital solutions, greater transparency in trial registration and data sharing, and integration of trials into national health systems.

The surging demand for integrated software solutions among pharmaceutical and biopharmaceutical companies is also serving as a major growth catalyst. These solutions streamline various aspects of clinical trials, from study planning and data capture to safety reporting and regulatory compliance. In addition, increasing government grants to support research activities, along with a rapidly widening end use base that includes CROs, academic institutions, and healthcare providers, is expected to further boost the adoption of clinical trials supporting software solutions during the forecast period.

Key market players such as Cytel, Dassault Systemes (via Medidata), Veeva Systems, IQVIA, Castor, Saama, Oracle, Parexel, Clario, Curebase, and Suvoda (post-merger with Greenphire) operate in a landscape characterized by increased strategic consolidation, AI innovation, and portfolio expansion. In April 2025, Suvoda merged with Greenphire to create a unified platform that integrates randomization, supply management, eConsent, eCOA, patient-centric payments, budgeting, and logistics, streamlining operations across the patient-to-site spectrum.

Companies are rapidly advancing toward integrated, AI-powered ecosystems that centralize trial functions and enable greater automation, scalability, and compliance. Recent developments reflect a strong focus on embedding solutions directly into clinical workflows, enabling real-time data capture, protocol optimization, and decentralized trial execution.

For instance, in January 2025, Medrio launched an AI-enabled reporting solution aimed at addressing the growing complexity of clinical trial data, offering real-time insights, automated workflows, and customizable dashboards to enhance trial oversight and decision-making. AI and machine learning are being leveraged to enhance patient-trial matching, predictive analytics, and risk-based monitoring, while the integration of payment automation and remote engagement tools is improving site satisfaction and trial efficiency. These trends indicate a shift from siloed point solutions to unified platforms capable of managing the entire clinical trial lifecycle driving faster, smarter, and more inclusive research outcomes.

Clinical Trials Support Software Solutions Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global clinical trials support software solutionsmarket report based on product, delivery mode, phase, end use, and regions.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Electronic Clinical Outcome Assessment (eCOA) / ePRO)
• Electronic Data Capture (EDC) & CDMS
• Clinical Analytics Platforms
• Clinical data integration platforms
• Safety solutions
• Clinical Trial Management System (CTMS)
• Randomization and Trial Supply Management (RTSM)
• Electronic Trial Master File (eTMF)
• eConsent
• Payments / Investigator Payments Solutions
• Electronic Investigator Site File (eISF)
• Patient Matching / Feasibility Solutions
• Delivery Mode Outlook (Revenue, USD Million, 2021 - 2033)
• Cloud and Web Based
• On-Premise
• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Phase I
• Phase II
• Phase III
• Phase IV (Post-marketing)
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals/Healthcare Providers/Healthcare providers
• Contract Research Organizations (CROs) (R&D covered)
• Academic & Research Institutions
• Pharmaceutical Companies
• Biopharmaceutical Companies
• Medical Device Companies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Delivery mode
  • 1.2.3. Phase
  • 1.2.4. End use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
    • 3.2.1.2. Rising R&D investments by pharmaceutical and biotechnology companies
    • 3.2.1.3. Rapid technological advancements such as AI, machine learning, and advanced analytics
    • 3.2.1.4. Increasing focus on patient-centric clinical trials
    • 3.2.1.5. Growing adoption of decentralized clinical trials (DCTs)
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. The high cost of implementing and maintaining clinical trial software solution
    • 3.2.2.2. Data privacy and security concerns, especially with cloud-based and decentralized platforms
    • 3.2.2.3. Limited digital infrastructure in developing and underdeveloped regions
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. Case Studies
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
    • 3.3.2.6. Social Landscape

Chapter 4. Clinical Trials Support Software Solutions Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Product Market Share Movement Analysis, 2024 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Electronic Clinical Outcome Assessment (eCOA) / ePRO
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Electronic Data Capture (EDC) & CDMS
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Clinical Analytics Platforms
  • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Clinical data integration platforms
  • 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Safety solutions
  • 4.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Clinical Trial Management System (CTMS)
  • 4.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.10. Randomization and Trial Supply Management (RTSM)
  • 4.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.11. Electronic Trial Master File (eTMF)
  • 4.11.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.12. eConsent
  • 4.12.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.13. Payments / Investigator Payments Solutions
  • 4.13.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.14. Electronic Investigator Site File (eISF)
  • 4.14.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.15. Patient Matching / Feasibility Solutions
  • 4.15.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Clinical Trials Support Software Solutions Market: Delivery Mode Estimates & Trend Analysis

• 5.1. Delivery Mode Dashboard
• 5.2. Delivery Mode Market Share Movement Analysis, 2024 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Delivery Mode, 2021 to 2033 (USD Million)
• 5.4. Cloud and web-based
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. On-premise
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Clinical Trials Support Software Solutions Market: Phase Estimates & Trend Analysis

• 6.1. Phase Segment Dashboard
• 6.2. Phase Market Share Movement Analysis, 2024 & 2033
• 6.3. Market Size & Forecasts and Trend Analysis, by Phase, 2021 to 2033 (USD Million)
• 6.4. Phase I
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Phase II
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Phase III
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Phase IV (Post-marketing)
  • 6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Clinical Trials Support Software Solutions Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. End Use Market Share Movement Analysis, 2024 & 2033
• 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Hospitals/Healthcare Providers/Healthcare providers
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Contract Research Organizations (CROs) (R&D covered)
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Academic & Research Institutions
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Pharmaceutical Companies
  • 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Biopharmaceutical Companies
  • 7.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Medical Device Companies
  • 7.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Clinical Trials Support Software Solutions Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market: Key Takeaways
• 8.3. North America
  • 8.3.1. North America Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key country dynamic
    • 8.3.2.2. Regulatory framework
    • 8.3.2.3. Competitive insights
    • 8.3.2.4. U.S. Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key country dynamic
    • 8.3.3.2. Regulatory framework
    • 8.3.3.3. Competitive insights
    • 8.3.3.4. Canada Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key country dynamic
    • 8.3.4.2. Regulatory framework
    • 8.3.4.3. Competitive insights
    • 8.3.4.4. Mexico Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamic
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive insights
    • 8.4.2.4. Germany Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. UK
    • 8.4.3.1. Key country dynamic
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive insights
    • 8.4.3.4. UK Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key country dynamic
    • 8.4.4.2. Regulatory framework
    • 8.4.4.3. Competitive insights
    • 8.4.4.4. France Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key country dynamic
    • 8.4.5.2. Regulatory framework
    • 8.4.5.3. Competitive insights
    • 8.4.5.4. Italy Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key country dynamic
    • 8.4.6.2. Regulatory framework
    • 8.4.6.3. Competitive insights
    • 8.4.6.4. Spain Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key country dynamic
    • 8.4.7.2. Regulatory framework
    • 8.4.7.3. Competitive insights
    • 8.4.7.4. Denmark Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key country dynamic
    • 8.4.8.2. Regulatory framework
    • 8.4.8.3. Competitive insights
    • 8.4.8.4. Sweden Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key country dynamic
    • 8.4.9.2. Regulatory framework
    • 8.4.9.3. Competitive insights
    • 8.4.9.4. Norway Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key country dynamic
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive insights
    • 8.5.2.4. Japan Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key country dynamic
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive insights
    • 8.5.3.4. China Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key country dynamic
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive insights
    • 8.5.4.4. India Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamic
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Competitive insights
    • 8.5.5.4. South Korea Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Australia
    • 8.5.6.1. Key country dynamic
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Competitive insights
    • 8.5.6.4. Australia Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Thailand
    • 8.5.7.1. Key country dynamic
    • 8.5.7.2. Regulatory framework
    • 8.5.7.3. Competitive insights
    • 8.5.7.4. Thailand Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Clinical trials support software solutions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key country dynamic
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive insights
    • 8.6.2.4. Brazil Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key country dynamic
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive insights
    • 8.6.3.4. Argentina Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key country dynamic
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive insights
    • 8.7.2.4. South Africa Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key country dynamic
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive insights
    • 8.7.3.4. Saudi Arabia Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key country dynamic
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive insights
    • 8.7.4.4. UAE Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key country dynamic
    • 8.7.5.2. Regulatory framework
    • 8.7.5.3. Competitive insights
    • 8.7.5.4. Kuwait Clinical trials support software solutions market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Cytel Inc. (acquired by Nordic Capital and Astorg)
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial performance
    • 9.5.1.3. Product benchmarking
    • 9.5.1.4. Strategic initiatives
  • 9.5.2. Dassault Systemes
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial performance
    • 9.5.2.3. Product benchmarking
    • 9.5.2.4. Strategic initiatives
  • 9.5.3. Veeva Systems
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial performance
    • 9.5.3.3. Product benchmarking
    • 9.5.3.4. Strategic initiatives
  • 9.5.4. IQVIA
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial performance
    • 9.5.4.3. Product benchmarking
    • 9.5.4.4. Strategic initiatives
  • 9.5.5. Castor
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial performance
    • 9.5.5.3. Product benchmarking
    • 9.5.5.4. Strategic initiatives
  • 9.5.6. Saama
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial performance
    • 9.5.6.3. Product benchmarking
    • 9.5.6.4. Strategic initiatives
  • 9.5.7. Oracle
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial performance
    • 9.5.7.3. Product benchmarking
    • 9.5.7.4. Strategic initiatives
  • 9.5.8. Parexel International Corporation
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial performance
    • 9.5.8.3. Product benchmarking
    • 9.5.8.4. Strategic initiatives
  • 9.5.9. Clario (formerly Bioclinica and ERT)
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial performance
    • 9.5.9.3. Products & Services benchmarking
    • 9.5.9.4. Strategic initiatives
  • 9.5.10. RealTime Software Solutions, LLC
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial performance
    • 9.5.10.3. Product benchmarking
    • 9.5.10.4. Strategic initiatives
  • 9.5.11. Curebase
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial performance
    • 9.5.11.3. Product benchmarking
    • 9.5.11.4. Strategic initiatives
  • 9.5.12. Suvoda LLC (merged with Greenphire in April 2025)
    • 9.5.12.1. Overview
    • 9.5.12.2. Financial performance
    • 9.5.12.3. Product benchmarking
    • 9.5.12.4. Strategic initiatives
  • 9.5.13. Medidata
    • 9.5.13.1. Overview
    • 9.5.13.2. Financial performance
    • 9.5.13.3. Product benchmarking
    • 9.5.13.4. Strategic initiatives
  • 9.5.14. ICON Plc
    • 9.5.14.1. Overview
    • 9.5.14.2. Financial performance
    • 9.5.14.3. Product benchmarking
    • 9.5.14.4. Strategic initiatives
  • 9.5.15. Thermo Fisher Scientific Inc.
    • 9.5.15.1. Overview
    • 9.5.15.2. Financial performance
    • 9.5.15.3. Product benchmarking
    • 9.5.15.4. Strategic initiatives
  • 9.5.16. Greenphire
    • 9.5.16.1. Overview
    • 9.5.16.2. Financial performance
    • 9.5.16.3. Product benchmarking
    • 9.5.16.4. Strategic initiatives
  • 9.5.17. TELEMEDICINE TECHNOLOGIES S.A.S.
    • 9.5.17.1. Overview
    • 9.5.17.2. Financial performance
    • 9.5.17.3. Product benchmarking
    • 9.5.17.4. Strategic initiatives